Year: 2019
Type: article
Abstract: miRNA‑223 (miR‑223) has been reported to function not only as a tumor suppressor, but also as an oncogenic microRNA (miRNA or miR) in various cancer cells. Therefore, the functional role of miR‑223 has not been elucidated to date, at least to the best of our knowledge. We previously performed the deep sequencing analysis of clinical bladder cancer (BC) specimens. It was revealed that miR‑223 expression was significantly downregulated in BC, suggesting that miR‑223 functions as a tumor suppressor miRNA in BC. The aim of this study was to investigate the functional roles of miR‑223 and to identify its targets in BC. The expression levels of miR‑223 were significantly decreased in our clinical BC specimens. The Cancer Genome Atlas (TCGA) database indicated that miR‑223 expression was related to lymphovascular invasion and distant metastasis. The restoration of miR‑223 expression significantly inhibited tumor aggressiveness and induced apoptosis via caspase‑3/7 activation in BC cells. WD repeat domain 62 (WDR62), a candidate target of miR‑223 according to in silico analyses, has been previously proposed to play a role in neurodevelopment. Direct binding between WDR62 and miR‑223 was confirmed by luciferase assay. The TCGA database revealed positive associations between WDR62 mRNA expression and a higher tumor grade and stage in BC. The knockdown of WDR62 significantly inhibited tumor aggressiveness and induced the apoptosis of BC cells. On the whole, the findings of this study reveal a novel miR‑223 target, oncogenic WDR62, and provided insight into the oncogenesis of BC.
Institution: Kagoshima University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
Awards: Development of the marker predicting GC primary resistance of the bladder cancer by multifaceted approach, Exploring molecular network of functional nucleic acid and developing therapeutic innovations in drug-resistant renal cell carcinoma, Elucidation of the resistance mechanism to the molecular targeting drug in renal cancer using the genome editing technology, Functional analyses of oncogenic microRNA by genome editing and development of innovative genome-based drug discovery for bladder cancer., Development of the innovative treatment based on the search of microRNA blocking growth signals in urothelial carcinoma, Targeting the Ubiquitin Proteasome Pathway as a Novel Therapeutic Strategy for Advanced Renal Cell Carcinoma
OpenAlex ID: W2923224548